Gastric Cancer: 66.7% Tumor Reduction and Durable 60-Week Complete Remission
08/05/2026
A novel nanobody-based CAR-T therapy targeting Claudin18.2 has demonstrated remarkable efficacy and safety in gastric and gastroesophageal junction cancers, achieving a 66.7% response rate and sustained complete remission beyond 60 weeks in early clinical trials.